| Literature DB >> 27154396 |
Abstract
Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer's disease. This article provides evidence-based recommendations to address the issues regarding the use of cholinesterase inhibitors and memantine in clinical practice. It includes their efficacy, timing, assessment, use in institutionalized patients, combined use, and use in other dementia types. However, most of the studies are of short duration (<1 year) and are mainly focused on cognitive and global improvement, whereas the practical issue of their use in daily practice such as optimal duration of treatment, long-term efficacy and delaying institutionalization are limited.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27154396 DOI: 10.1007/s40266-016-0372-3
Source DB: PubMed Journal: Drugs Aging ISSN: 1170-229X Impact factor: 3.923